Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

GLP-1 and cardioprotection: from bench to bedside

(2012) S. Ravassa et al.   CARDIOVASCULAR RESEARCH

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

(2012) Mohammad Hossein Noyan-Ashraf et al.   CIRCULATION

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism

(2012) W. Chai et al.   DIABETES

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats

(2012) Soo Lim et al.   PLoS One

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

(2011) Meimei Yin et al.   Cardiovascular Diabetology

Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway

(2011) Yong-Fu Xiao et al.   Cardiovascular Diabetology

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

(2011) Jacob Lønborg et al.   EUROPEAN HEART JOURNAL

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

(2010) Yumei Ye et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis

(2010) Hans D. Theiss et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction

(2009) Marc-Michael Zaruba et al.   Cell Stem Cell

Glucose Deprivation Regulates K ATP Channel Trafficking via AMP-Activated Protein Kinase in Pancreatic β-Cells

(2009) Ajin Lim et al.   DIABETES

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

(2009) Leo Timmers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS

GLP-1 Therapy

(2008) Derek J. Hausenloy et al.   Circulation-Heart Failure

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

(2008) Indu Poornima et al.   Circulation-Heart Failure